(CDK/MAPK/GSK3/CLK) are a kinase group which regulate proliferation, expression, differentiation, mitosis, cell survival, and apoptosis, among many others.
We found a novel mechanism where a simple molecule as metformin is able to modulate and create a synergy interaction with the kinase group. Reduced doses of chemotherapy with a increased affectivity, less relapse and less resistance to novel treatments were some of our clinical findings in more than one hundred different tumor genotypes.
The use of stronger and specific ativators can increase a fatal outcome in patients depending of tumor grade where metformin is well tolerated.
Find a balance between a stronger and multiple Kinase activators with more efficacy and less side effects will be our next challenge.
Luis Llorente
Oncostop Foundation
searchcancer@gmail.comNingún hospital consultado hasta ahora puede permitirse el gasto de una investigación sin subvenciones o patrocinadores.
No hay comentarios:
Publicar un comentario